← Eichor
Study identifier: NCT06803745 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

Condition: Acute Leukemia · Acute Lymphoblastic Lymphoma  ·  Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

PhaseNA
Planned participants160
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow Transplantation (BMT). The primary objective is to compare the rates of graft-versus-host disease-free and relapse-free survival (GRFS) between patients in the two cohorts.

This description comes directly from the study's public registry record.

Talk to the study team

Jonathan Webster, MD  ·  410-614-9106  ·  jwebst17@jhmi.edu

Preston Clairborne, MD  ·  4109558893  ·  jclaibo8@jh.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06803745